Early methylphenidate findings

Attention-deficit/hyperactivity disorder is a childhood condition that affects focus, impulse control, and activity level, and methylphenidate is one of the main medicines used to treat it. A new 2026 study found no overall increase in later psychotic disorders among children and teens with ADHD who took methylphenidate, and it found a possible protective effect in those diagnosed before age 13. (jamanetwork.com) The JAMA Psychiatry study used Finnish national registry data on 697,289 people born from 1987 to 1997 and identified 3,956 children and adolescents later diagnosed with ADHD. Among that ADHD group, 2,728 people, or 69.0%, received methylphenidate at least once, and 222, or 5.7%, were diagnosed with nonaffective psychosis by a mean age of 22.16 years. (jamanetwork.com) The authors reported no overall long-term difference in psychosis risk between treated and untreated patients. In a subgroup analysis, children diagnosed with ADHD before age 13 showed what the paper called a “potential protective effect” from sustained methylphenidate treatment against later psychotic disorder. (jamanetwork.com) That result lands in a field shaped by years of concern that stimulant drugs might trigger psychosis. The Food and Drug Administration’s current Ritalin label says recommended doses can cause psychotic or manic symptoms in some patients, even without a prior history of those symptoms. (accessdata.fda.gov) Other recent research has moved in the same direction on one narrow point: the medicine itself may not be the cause of psychosis risk seen in some ADHD patients. An ADDitude report on a 2025 Pediatrics study said researchers followed 8,391 children ages 9 to 14 and found the apparent link between stimulant use and psychotic experiences was better explained by other factors, including more severe ADHD symptoms and other mental health conditions. (additudemag.com) Long-term psychiatric outcomes remain unsettled, though, and the evidence does not all ask the same question. A 2022 South Korean cohort study specifically examined long-term methylphenidate use and tracked depression, conduct disorder, and psychotic disorder risk in children and adolescents with ADHD. (ncbi.nlm.nih.gov) Safety reviews also continue to list psychiatric side effects as a real monitoring issue. A 2025 narrative review said methylphenidate improves attention by increasing dopamine and norepinephrine signaling, but it also said anxiety, agitation, psychotic symptoms, and worsening mood disorders require careful follow-up, especially during long-term treatment. (link.springer.com) The treatment debate matters because ADHD is common and usually starts early. The Centers for Disease Control and Prevention says 7 million U.S. children ages 3 to 17, or 11.4%, had ever been diagnosed with ADHD as of 2022. (cdc.gov) U.S. guidelines already frame ADHD care as more than a medication decision. The American Academy of Pediatrics says treatment for children and adolescents should address ADHD as a chronic condition and can include stimulant medication, behavior therapy, and coordination with schools. (aap.org) ADDitude’s article went further than the psychosis paper alone by describing two studies and linking early methylphenidate use to later risks including psychiatric disorders and post-traumatic stress disorder. Without the primary paper for that second claim, the clearest verified takeaway is narrower: one large 2026 registry study found no overall long-term psychosis increase and a possible benefit in children diagnosed before 13, but the authors and outside coverage both leave that finding in the “needs replication” category. (additudemag.com, jamanetwork.com, nbcnews.com)